BMS Prepares Orencia Launch In Japan, Aiming For First-line RA Treatment
This article was originally published in PharmAsia News
Executive Summary
Nagoya University medical professor Naoki Ishimuro said new rheumatoid drug Orencia (abatacept) will bring benefits to patients who are not responding to current therapies